Cogent Biosciences (COGT) Stock Statistics & Valuation Metrics

Cogent Biosciences has a market cap or net worth of $6.22B. The enterprise value is $5.67B.

Cogent Biosciences has 162,308,820 shares outstanding. The number of shares has decreased by -2.65% in one year.

Cogent Biosciences’s return on equity (ROE) is -0.52 and return on invested capital (ROIC) is -38.09%.

The current PE Ratio of Cogent Biosciences is ―. Cogent Biosciences’s PEG ratio is -2.00.

In the last 12 months, Cogent Biosciences had revenue of 0.00 and earned -328.94M in profits. Earnings per share was -2.55.

In the last 12 months, operating cash flow was -264.44M and capital expenditures -1.55M, giving a free cash flow of -266.00M billion.

Cogent Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Cogent Biosciences upcoming earnings date is May 12, 2026, TBA (Confirmed).

Cogent Biosciences as a current ratio of 14.23, with Debt / Equity ratio of 39.78%

In the past 12 months, Cogent Biosciences has paid 0.00 in taxes.

Cogent Biosciences EV to EBITDA ratio is -7.12, with an EV/FCF ratio of -8.81.

Cogent Biosciences has $900.76M in cash and marketable securities with $253.15M in debt, giving a net cash position of $647.61M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Cogent Biosciences is $52.18, which is 11.43% higher than the current price. The consensus rating is Strong Buy